SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma
Background: Patients resected for clinically detected stage III melanoma have a high risk of recurrence and death from melanoma. At present two studies (SWOG S1801 and NADINA) have demonstrated superiority when using neoadjuvant treatment compared to adjuvant treatment only, but no studies have compared aPD-1 monotherapy to the aPD-1/aCTLA-4 combination therapy. The SWE-NEO trial aims to compare these two regimens, where the aPD-1/aCTLA-4 combination is potentially more effective, but also associated with more side effects.
Authors
- Roger Olofsson Bagge (ORCID: https://orcid.org/0000-0001-5795-0355)
- Göran Jönsson (ORCID: https://orcid.org/0000-0002-4436-7977)
- Sara A. Wickström (ORCID: https://orcid.org/0000-0001-6383-6292)
- Hildur Helgadóttir (ORCID: https://orcid.org/0000-0002-0735-4771)
- Lars Ny (ORCID: https://orcid.org/0000-0003-3864-5958)
- Ana Carneiro (ORCID: https://orcid.org/0000-0002-1818-7008)
- Karl Björkström (ORCID: https://orcid.org/0000-0002-9688-8870)
- Jonas A. Nilsson (ORCID: https://orcid.org/0000-0003-0346-6837)
- Anders Berglund (ORCID: https://orcid.org/0000-0003-3698-9861)
Institutions
- Sahlgrenska University Hospital (SE)
- Karolinska Development (Sweden) (SE)
- Skåne University Hospital (SE)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100639
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05